Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia

A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli

Status

Not yet recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07612605

Enrollment

250

Registered

2026-05-29

Start date

2026-06-01

Completion date

2029-12-31

Last updated

2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Keywords

bacteriophage, Yiqi Huoxue Jiedu Formula, drug-resistant bacteria, Pneumonia

Brief summary

Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.

Interventions

DRUGYHDF placebo

7-14 days treatment with YHDF placebo

DRUGBacteriophage Placebo

7-14 days treatment with bacteriophage placebo

DRUGYHDF Drug

7-14 days treatment with YHDF

DRUGBacteriophage

7-14 days treatment with bacteriophage

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome; * Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa; * Aged 18 to 85 years old; * Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy; * Patients or their family members have fully read, understood and signed the informed consent form.

Exclusion criteria

* Women who are pregnant or lactating; * Patients with immunodeficiency; * Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases; * Patients who have received mechanical ventilation for more than 60 days prior to enrollment; * Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD); * Patients with incomplete sampling or clinical data; * Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula; * Patients judged by the researchers as unsuitable for participation in this study.

Design outcomes

Primary

Measure	Time frame
Clearance rate of drug-resistant bacteria	14 days

Secondary

Measure	Time frame
Time to clinical improvement	7 days
All-cause mortality	28 days

Countries

China

Contacts

CONTACTJianqiao Xu

774690118@qq.com8617310692712

CONTACTCongyang Zheng

zhengcy1025@outlook.com8618323063716

STUDY_DIRECTORLixin Xie

College of Pulmonary and Critical Care Medicine, Chinese PLA General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026